Clinical Trial Update: Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates carboplatin and paclitaxel with or without panitumumab in invasive triple-negative breast cancer. The study status is active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer
• Invasive Breast Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Panitumumab (panitumumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Carcinoma, Breast Lump | Phase 2 | Status: ACTIVE_NOT_RECRUITING